Metabolic · 99.82% Purity

Retatrutide Research Peptide

Retatrutide is a triple hormone receptor agonist that targets the GIP, GLP-1, and glucagon receptors simultaneously, studied in advanced metabolic and body-weight research.

$145.00 · 10mg · Research Use Only

Research Applications

Metabolic pathway modulation, adipogenesis inhibition, energy expenditure studies.

Specifications

Size

10mg

Purity

99.82%

Batch

26030313

Verified By

Janoshik Analytical

Research Overview

Retatrutide (LY3437943) is a first-in-class triple agonist of the GIP, GLP-1, and glucagon receptors. In a Phase 2 clinical trial published in the New England Journal of Medicine (2023), participants receiving retatrutide achieved up to 17.5% mean weight reduction at 24 weeks — among the highest reported for any pharmacological intervention in obesity research to date. Preclinical studies demonstrate its role in suppressing adipogenesis and increasing whole-body energy expenditure through complementary receptor pathways.

Certificate of Analysis

View Certificate of Analysis (PDF) — batch 26030313, verified by Janoshik Analytical at 99.82% purity.

Published research

Read the full Retatrutide research guide →

For laboratory research use only. Not for human consumption.